

**Beneficiary Advisory Panel Handout
Uniform Formulary Decisions
21 June 2012**

PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.

Table 1: Smoking Cessation Agents

Formulary Agents: Varenicline tablets (brand name Chantix)
Bupropion SR tablets (brand name Zyban and generics)
Nicotine nasal spray (brand name Nicotrol NS)
Nicotine inhalation (brand name Nicotrol)
Nicotine transdermal (brand names Nicoderm CQ and Habitrol)
Nicotine Gum (brand names Nicorette, Nicorelief, and generics)
Nicotine Lozenge (brand names Nicorette)

Non-Formulary: None

Recommended implementation period for program: 60 days upon signing of the final rule

Table 2: Newer Sedative Hypnotics

Formulary: Zolpidem IR tablets (brand name Ambien and generics)
Zaleplon capsules (brand name Sonata and generics)

Formulary with documented trial or contraindication for Zolpidem IR (Ambien) and Zaleplon (Sonata):
Zolpidem controlled release tablets (brand name Ambien CR and generics)
Doxepin tablets (brand name Silenor)
Eszopiclone tablets (brand name Lunesta)

Non-formulary with a documented trial or contraindication for Zolpidem IR (Ambien) and Zaleplon (Sonata):
Ramelteon tablets (brand name Rozerem)
Zolpidem sublingual tablets (brand name Edluar)

Not covered: Zolpidem spray (brand name Zolpimist) declined to participate in the FSS/VHCA pricing program

Recommended implementation period 60 days

Figure 1: Newer Sedative Hypnotics – 30-Day Equivalents in All POS




Table 3: Non-opioid Pain Syndrome Agents

GABA Analog Subclass

Formulary: Gabapentin immediate release (brand name Neurontin and generics)

Non-formulary with a documented trial or contraindication for gabapentin IR

(Neurontin/generics):

Pregabalin (brand name Lyrica)

Gabapentin enacarbil (brand name Horizant)

Gabapentin extended release (brand name Gralise)

Implementation Plan: N/A

Figure 2: Non-opioid Pain Syndrome Agents – Utilization in 30-Day Equivalents in All POS




Table 4: Table of Implementation Status of UF Recommendations/Decisions Summary Table

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Step Therapy
				MTF	Retail	Mail Order		
May 2012	Newer Sedative Hypnotics	Zolpidem spray (Zolpimist)	82	0	72	10	60 days	NA
	Non-opioid Pain Syndrome Agents	Gabapentin enacarbil (Horizant)	1216	14	1009	193	30 days	Must try gabapentin IR (Neurontin/generics)
		Gabapentin extended release (Gralise)	527	3	485	39		